Randox Laboratories (India) Private Limited - Due diligence report

A 360° intelligence report on Randox Laboratories: trust score, financial health, credit view, compliance, directors, growth and distress si…

2004-12-28 Bangalore, Karnataka Active Unlisted Active Compliant
Share
Connect MCP
RL Randox Laboratories (India) Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Randox Laboratories — 360° Intelligence Report

Generated from MCA filings & public records
71/100
Trust Score
Moderate

Randox Laboratories is assessed as Moderate with a Trust Score of 71/100. Randox Laboratories is an active private limited indian non-government company incorporated in 2004, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 16 Aug 2026 from the latest processed filings. Randox Laboratories (India) Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
71/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
90/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
20/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.

Charges position: 1 open (80.00 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Citi Bank N.A.1 48.0 cr
Compliance Score: 90/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 2 auditor resignation(s) filed - latest: B S R & Co. LLP on 2020-05-11.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
UMESH 01234567 Director 01/04/2018 6 yrs Approved
STEPHEN PETER FITZGERALD 01234567 Director 01/04/2018 6 yrs Approved
Linda Ann Magee 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Randox Laboratories Limited United Kingdom
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Randox Laboratories Limited United Kingdom Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 70
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Asset base grew 1.42 - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Negative net worth.
1 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment46/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 80.00 Lakh already registered.
  • Compliance record supports lending.
Investor view57/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
31 Dec 2025
Last AGM held
Annual general meeting
30 Dec 2025
Director ceased
Linda Ann Magee
10 Apr 2025
Director appointed
Linda Ann Magee (Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Nov 2022
Director ceased
UMESH
08 Aug 2022
Director appointed
UMESH (Director)
Director ceased
PRASHANT SURESH SHANBHAG
30 Sep 2019
Director ceased
RICHARD KELLY
28 Jan 2019
Director ceased
BRIAN WALSH
03 Sep 2018
Director ceased
BISWA JYOTI SAHOO
29 Jan 2016
Director ceased
ASHWIN DINAKARAN
06 Jun 2014
Charge created
Citi Bank N.A. - 80.00 Lakh
31 Dec 2012
Director ceased
SONYA MARIA FERGUSON
28 May 2009
Securities allotted
8871970.00 Equity Shares - 8.87 cr raised
14 Feb 2008
Director ceased
SREERAM GOPAL
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Cosmas Research Lab Limited U24110PB2008PLC031925 Ludhiana, Punjab, India
Zeiss Pharmaceuticals Private Limited U24200HP2004PTC026909 Nalagarh, Himachal Pradesh, India
Monolithisch India Limited L26999WB2018PLC227534 Neturia, West Bengal, India
Lupin L24100MH1983PLC029442 Mumbai, Maharashtra, India
Hughes And Hughes Chem Limited U24100DL1991PLC045290 New Delhi, Delhi, India
Aroma Magic U24246DL1993PTC052106 New Delhi, Delhi, India
Valens Molecules U24100TG1994PTC018680 Hyderabad,, Telangana, India
Consern Pharma U24232PB2001PLC024715 Ludhiana, Punjab, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Randox Laboratories before audits and certifications: compliance score 90/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Randox Laboratories: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 80/100, margin trends, ownership structure and peer set for Randox Laboratories - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 71/100, distress signals and MSME payment-delay disclosures - know whether Randox Laboratories pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Randox Laboratories - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Randox Laboratories an active company?

Randox Laboratories has MCA status “Active” with a compliance score of 90/100 (Low Risk).

Is Randox Laboratories financially healthy?

Randox Laboratories has a Financial Health Score of 20/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Randox Laboratories?

Its overall Trust Score is 71/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Randox Laboratories?

The ultimate holding entity is Randox Laboratories Limited United Kingdom. 3 active director(s) are on record.

Does Randox Laboratories have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Randox Laboratories up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 90/100 (Low Risk).

Is it risky to lend to Randox Laboratories?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.